NCT02724332

Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC

A Randomized Controlled Study on the Effect of Adjuvant Anti-recurrence Treatment With Rapamycin on Early-stage HCC With Overexpression of ASPH After Radical Surgery.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 300 (actual)
• Sponsor: Eastern Hepatobiliary Surgery Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the clinical effect of rapamycin combined with TACE on early-stage HCC with overexpression of ASPH after radical surgery using randomized controlled study and provide a new anti-recurrence treatment for HCC patients after operation.

Conditions

• Hepatocellular Carcinoma
• Rapamycin

Interventions

Type	Name	Description
DRUG	Rapamycin	2mg,po,bid

Timeline

• Start date: 2012-11-01
• Primary completion: 2015-06-01
• Completion: 2015-12-01
• First posted: 2016-03-31
• Last updated: 2016-03-31

Locations

1 site across 1 country: China